Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease

BACKGROUND: Use of enzyme replacement therapy (ERT) to treat Fabry disease, caused by deficient lysosomal α-galactosidase A activity, can lead to formation of neutralizing antidrug antibodies (ADAs). These antibodies are associated with increased accumulation of plasma globotriaosylceramide (Gb3) an...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Am Soc Nephrol
Главные авторы: Lenders, Malte, Neußer, Leon Paul, Rudnicki, Michael, Nordbeck, Peter, Canaan-Kühl, Sima, Nowak, Albina, Cybulla, Markus, Schmitz, Boris, Lukas, Jan, Wanner, Christoph, Brand, Stefan-Martin, Brand, Eva
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Nephrology 2018
Предметы:
Clinical Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6287863/
https://ncbi.nlm.nih.gov/pubmed/30385651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2018070740
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы